Improving the tolerability of anticholinergic agents in the treatment of overactive bladder

Drug Safety

Volumn 28, Issue 7, 2005, Pages 583-600

  Dmochowski, Roger ^a,b  

^a VANDERBILT UNIVERSITY   (United States)

^b VANDERBILT UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINERGIC RECEPTOR BLOCKING AGENT; DARIFENACIN; MUSCARINIC RECEPTOR BLOCKING AGENT; OXYBUTYNIN; SOLIFENACIN; TOLTERODINE; TROSPIUM CHLORIDE;

CLINICAL TRIAL; CONSTIPATION; DEPRESSION; DIZZINESS; DRUG ABSORPTION; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG METABOLISM; DRUG RELEASE; DRUG TARGETING; DRUG TOLERABILITY; DRY SKIN; FIRST PASS EFFECT; HEADACHE; HUMAN; NAUSEA; OVERACTIVE BLADDER; PRIORITY JOURNAL; REVIEW; SOMNOLENCE; VISUAL IMPAIRMENT; XEROSTOMIA;

ADMINISTRATION, ORAL; CHOLINERGIC ANTAGONISTS; DELAYED-ACTION PREPARATIONS; HUMANS; TREATMENT OUTCOME; URINARY INCONTINENCE;

EID: 22344437553     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200528070-00003     Document Type: Review

References (89)

1. Wein AJ, Rovner ES. Definition and epidemiology of overactive bladder. Urology 2002; 60: 7-12; discussion 12
2. Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology 2003; 61: 37-49
3. Burgio KL, Ives DG, Locher JL, et al. Treatment seeking for urinary incontinence in older adults. J Am Geriatr Soc 1994; 42: 208-12
4. Dugan E, Roberts C, Cohen S, et al. Why older community-dwelling adults do not discuss urinary incontinence with their primary care physicians. J Am Geriatr Soc 2001; 49: 462-5
5. Van Oyen H, Van Oyen P. Urinary incontinence in Belgium; prevalence, correlates and psychosocial consequences. Acta Clin Belg 2002; 57: 207-18
6. Stewart W, Herzog R, Wein A, et al. Prevalence of and impact of overactive bladder in the U.S.: results from the NOBLE Program. Neurourol Urodyn 2001; 20: Abstract 406
7. Ouslander JG. Management of overactive bladder. N Engl J Med 2004; 350: 786-99
8. Bulmer P, Abrams P. The unstable detrusor. Urol Int 2004; 72: 1-712
9. Bogner HR, Gallo JJ, Sammel MD, et al. Urinary incontinence and psychological distress in community-dwelling older adults. J Am Geriatr Soc 2002; 50: 489-95
10. Steers WD, Lee K. Depression and incontinence. World J Urol 2001; 19: 351-7
11. Thom DH, Haan MN, Van Den Eeden SK. Medically recognized urinary incontinence and risks of hospitalization, nursing home admission and mortality. Age Ageing 1997; 26: 367-74
12. Chess-Williams R. Muscarinic receptors of the urinary bladder: detrusor, urothelial and prejunctional. Auton Autacoid Pharmacol 2002; 22: 133-45
13. Caulfield MP, Birdsall NJ. International Union of Pharmacology. XVII. Classification of muscarinic acetylcholine receptors. Pharmacol Rev 1998; 50: 279-90
14. Chapple CR, Yamanishi T, Chess-Williams R. Muscarinic receptor subtypes and management of the overactive bladder. Urology 2002; 60: 82-88; discussion 88-9
15. Andersson KE. The overactive bladder: pharmacologic basis of drug treatment. Urology 1997; 50: 74-84; discussion 85-79
16. Yamaguchi O, Shishido K, Tamura K, et al. Evaluation of mRNAs encoding muscarinic receptor subtypes in human detrusor muscle. J Urol 1996; 156: 1208-13
17. Wang P, Luthin GR, Ruggieri MR. Muscarinic acetylcholine receptor subtypes mediating urinary bladder contractility and coupling to GTP binding proteins. J Pharmacol Exp Ther 1995; 273: 959-66
18. Barras M, Coste A, Eon MT, et al. Pharmacological characterization of muscarinic receptors implicated in rabbit detrusor muscle contraction and activation of inositol phospholipid hydrolysis in rabbit detrusor and parotid gland. Fundam Clin Pharmacol 1999; 13: 562-70
19. Sawyer GW, Lambrecht G, Ehlert FJ. Functional role of muscarinic M(2) receptors in alpha,beta-methylene ATP induced, neurogenic contractions in guinea-pig ileum. Br J Pharmacol 2000; 129: 1458-64
20. Igawa Y. Discussion: functional role of M(1), M(2), and M(3) muscarinic receptors in overactive bladder. Urology 2000; 55: 47-49; discussion 50
21. Burgio K, Locher J, Goode P, et al. Behavioral vs drug treatment of urge urinary incontinence in older women; a randomized controlled trial. JAMA 1998; 280: 1995-2000
22. Eriksen BC, Bergmann S, Mjolnerod OK. Effect of anal electrostimulation with the 'Incontan' device in women with urinary incontinence. Br J Obstet Gynaecol 1987; 94: 147-56
23. Rovner ES, Wein A. The treatment of overactive bladder in the geriatric patient. Clinical Geriatrics 2002; 10: 20-35
24. Burgio K, Locher J, Goode P. Combined behavioral and drug therapy for urge incontinence in older women. J Am Geriatr Soc 2000; 48: 370-4
25. Dmochowski RR, Sand PK, Zinner NR, et al. Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence. Urology 2003; 168: 580-6
26. Van Kerrebroeck P, Kreder K, Jonas U, et al. Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder. Urology 2001; 57: 414-21
27. Millard R, Tuttle J, Moore K, et al. Clinical efficacy and safety of tolterodine compared to placebo in detrusor overactivity. J Urol 1999; 161: 1551-5
28. Thuroff JW, Bunke B, Ebner A, et al. Randomized, double-blind, multicenter trial on treatment of frequency, urgency and incontinence related to detrusor hyperactivity: oxybutynin versus propantheline versus placebo. J Urol 1991; 145: 813-816; discussion 816-7
29. Tapp AJ, Cardozo LD, Versi E, et al. The treatment of detrusor instability in post-menopausal women with oxybutynin chloride: a double blind placebo controlled study. Br J Obstet Gynaecol 1990; 97: 521-6
30. Lawrence M, Guay DR, Benson SR, et al. Immediate-release oxybutynin versus tolterodine in detrusor overactivity: a population analysis. Pharmacotherapy 2000; 20: 470-5
31. Nilvebrant L, Andersson KE, Gillberg PG, et al. Tolterodine: a new bladder-selective antimuscarinic agent. Eur J Pharmacol 1997; 327: 195-207
32. Gillberg PG, Sundquist S, Nilvebrant L. Comparison of the in vitro and in vivo profiles of tolterodine with those of subtype-selective muscarinic receptor antagonists. Eur J Pharmacol 1998; 349: 285-92
33. Pak RW, Petrou SP, Staskin DR. Trospium chloride: a quaternary amine with unique pharmacologic properties. Curr Urol Rep 2003; 4: 436-40
34. Kershen RT, Hsieh M. Preview of new drugs for overactive bladder and incontinence: darifenacin, solifenacin, trospium, and duloxetine. Curr Urol Rep 2004; 5: 359-67
35. 2+ mobilization study in monkey cells. Life Sci 2004; 74: 843-53
36. Hatanaka T, Ukai M, Ohtake A, et al. In vitro tissue selectivity profile of solifenacin succinate (YM905) for urinary bladder over salivary gland in rats and monkeys [abstract 312]. Presented at the International Continence Society Meeting. Florence, Italy: 2003 Oct 5-9
37. Ohtake A, Hatanaka T, Ikeda K, et al. In vivo bladder selective profile of solifenacin succinate (YM905) over salivary gland in mice and rats. Presented at the International Continence Society Meeting [Abstract 297]. Florence, Italy: October 5-9, 2003
38. Newgreen DT, Anderson DW, Carter AJ, et al. Darifenacin: a novel bladder-selective agent for the treatment of urge incontinence. Neurourol Urodyn 1995, 557
39. Riva D, Casolati E. Oxybutynin chloride in the treatment of female idiopathic bladder instability: results from double blind treatment. Clin Exp Obstet Gynecol 1984; 11: 37-42
40. Douchamps J, Derenne F, Stockis A, et al. The pharmacokinetics of oxybutynin in man. Eur J Clin Pharmacol 1988; 35: 515-20
41. Hughes KM, Lang JC, Lazare R, et al. Measurement of oxybutynin and its N-desethyl metabolite in plasma, and its application to pharmacokinetic studies in young, elderly and frail elderly volunteers. Xenobiotica 1992; 22: 859-69
42. Yarker YE, Goa KL, Fitton A. Oxybutynin: a review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in detrusor instability. Drugs Aging 1995; 6: 243-62
43. Ditropan XL (package insert). Mountain View (CA): ALZA Corporation, 2000
44. Gupta SK, Shah J, Sathyan G. Evidence for site-specific presystemic metabolism of oxybutynin following oral administration. In: Reidenberg MM, editor. 98th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics; 1997 Mar 5-8; San Diego (CA): 227
45. Buyse G, Waldeck K, Verpoorten C, et al. Intravesical oxybutynin for neurogenic bladder dysfunction: less systemic side effects due to reduced first pass metabolism. J Urol 1998; 160: 892-6
46. Zobrist RH, Quan D, Thomas HM, et al. Pharmacokinetics and metabolism of transdermal oxybutynin: in vitro and in vivo performance of a novel delivery system. Pharm Res 2003; 20: 103-9
47. Waldeck K, Larsson B, Andersson KE. Comparison of oxybutynin and its active metabolite, N-desethyl-oxybutynin, in the human detrusor and parotid gland. J Urol 1997; 157: 1093-7
48. Gupta SK, Sathyan G. Pharmacokinetics of an oral once-a-day controlled-release oxybutynin formulation compared with immediate-release oxybutynin. J Clin Pharmacol 1999; 39: 22-9
49. Oxytrol (package insert). Corona (CA): Watson Pharma, Inc., 2003
50. Detrol (package insert). Kalamazoo (MI): Pharmacia and Upjohn Company, 2002
51. Detrol LA (package insert). Kalamazoo (MI): Pharmacia and Upjohn Company, 2002
52. Appell RA. Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: a pooled analysis. Urology 1997; 50: 90-96; discussion 97-9
53. Abrams P, Freeman R, Anderstrom C, et al. Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder. Br J Urol 1998; 81: 801-10
54. Harvey MA, Baker K, Wells GA. Tolterodine versus oxybutynin in the treatment of urge urinary incontinence: a meta-analysis. Am J Obstet Gynecol 2001; 185: 56-61
55. Appell RA, Sand P, Dmochowski R, et al. Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT study. Mayo Clin Proc 2001; 76: 358-63
56. Diokno AC, Appell RA, Sand PK, et al. Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial. Mayo Clin Proc 2003; 78: 687-95
57. Drutz HP, Appell RA, Gleason D, et al. Clinical efficacy and safety of tolterodine compared to oxybutynin and placebo in patients with overactive bladder. Int Urogynecol J Pelvic Floor Dysfunct 1999; 10: 283-9
58. Guay DR. Clinical pharmacokinetics of drugs used to treat urge incontinence. Clin Pharmacokinet 2003; 42: 1243-85
59. Olsson B, Szamosi J. Multiple dose pharmacokinetics of a new once daily extended release tolterodine formulation versus immediate release tolterodine. Clin Pharmacokinet 2001; 40: 227-35
60. Brynne N, Stahl MM, Hallen B, et al. Pharmacokinetics and pharmacodynamics of tolterodine in man: a new drug for the treatment of urinary bladder overactivity. Int J Clin Pharmacol Ther 1997; 35: 287-95
61. Postlind H, Danielson A, Lindgren A, et al. Tolterodine, a new muscarinic receptor antagonist, is metabolized by cytochromes P450 2D6 and 3A in human liver microsomes. Drug Metab Dispos 1998; 26: 289-93
62. Cardozo L, Chapple CR, Toozs-Hobson P, et al. Efficacy of trospium chloride in patients with detrusor instability: a placebo-controlled, randomized, double-blind, multicentre clinical trial. BJU Int 2000; 85: 659-64
63. Zinner N, Gittelman M, Harris R, et al. Trospium chloride improves overactive bladder symptoms: a multicenter phase III trial. J Urol 2004; 171: 2311-5
64. Halaska M, Ralph G, Wiedemann A, et al. Controlled, double-blind, multicenter clinical trial to investigate long-term tolerability and efficacy of trospium chloride in patients with detrusor instability. World J Urol 2003; 20: 392-9
65. Sanctura (package insert). Florham Park (NJ): Odyssey Pharmaceuticals, Inc. and Indevus Pharmaceuticals, Inc, 2005
66. Chapple CR, Rechberger T, Al Shukri S, et al. Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU Int 2004; 93: 303-10
67. Cardozo L, Lisec M, Millard R, et al. Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. J Urol 2004; 172: 1919-24
68. Ikeda K, Kobayashi S, Suzuki M, et al. M(3) receptor antagonism by the novel antimuscarinic agent solifenacin in the urinary bladder and salivary gland. Naunyn Schmiedebergs Arch Pharmacol 2002; 366: 97-103
69. Gleason DM, Susset J, White C, et al. Evaluation of a new once-daily formulation of oxybutynin for the treatment of urinary urge incontinence: Ditropan XL Study Group. Urology 1999; 54: 420-3
70. Anderson RU, Mobley D, Blank B, et al. Once daily controlled versus immediate release oxybutynin chloride for urge urinary incontinence: OROS Oxybutynin Study Group. J Urol 1999; 161: 1809-12
71. Chapple CR. Darifenacin is well tolerated and provides significant improvement in the symptoms of overactive bladder: a pooled analysis of phase III studies. J Urol. 2004; 171: 130
72. 3 selective muscarinic receptor antagonist is effective and well tolerated by elderly patients with overactive bladder. J Am Geriatr Soc 2004; 52 (suppl 4): S126
73. 3 selective receptor antagonist, reduces the frequency of nocturnal awakening, an important symptom of overactive bladder. J Urol 2004; 171 (suppl 4): 131
74. Enablex® (package insert). East Hanover (NJ): Novartis Pharmaceuticals, 2004
75. VESIcare® (package insert). Research Triangle Park (NC): GlaxoSmithKline, 2004
76. Zobrist RH, Schmid B, Feick A, et al. Pharmacokinetics of the R- and S-enantiomers of oxybutynin and N-desethyloxybutynin following oral and transdermal administration of the racemate in healthy volunteers. Pharm Res 2001; 18: 1029-34
77. Appell RA, Chancellor M, Zobrist RH, et al. Pharmacokinetics, metabolism, and saliva output during transdermal and extended-release oral oxybutynin administration in healthy subjects. Mayo Clin Proc 2003; 78: 696-702
78. Illustration of transdermal delivery systems. Corona (CA): Watson Pharma Inc., 2003. (Data on file)
79. Davila GW, Daugherty CA, Sanders SW. A short-term, multicenter, randomized double-blind dose titration study of the efficacy and anticholinergic side effects of transdermal compared to immediate release oral oxybutynin treatment of patients with urge urinary incontinence. J Urol 2001; 166: 140-5
80. Dmochowski RR, Davila GW, Zinner NR, et al. Efficacy and safety of transdermal oxybutynin in patients with urge and mixed urinary incontinence. J Urol 2002; 168: 580-6
81. Radziszewski P, Borkowski A. Therapeutic effects of intrarectal administration of oxybutynin [in Polish]. Wiad Lek 2002; 55: 691-8
82. Winkler HA, Sand PK. Treatment of detrusor instability with oxybutynin rectal suppositories. Int Urogynecol J Pelvic Floor Dysfunct 1998; 9: 100-2
83. Collas D, Malone-Lee J. The pharmacokinetic properties of rectal oxybutynin: a possible alternative to intravesical administration. In: ICS 27th Annual Meeting; 1997 Sep 23-26; Yokohama, Japan: Neurourology and Urodynamics; 1997: 346
84. Weese DL, Roskamp DA, Leach GE, et al. Intravesical oxybutynin chloride: experience with 42 patients. Urology 1993; 41: 527-30
85. Saito M, Tabuchi F, Otsubo K, et al. Treatment of overactive bladder with modified intravesical oxybutynin chloride. Neurourol Urodyn 2000; 19: 683-8
86. Cannon TW, Chancellor MB. Pharmacotherapy of the overactive bladder and advances in drug delivery. Clin Obstet Gynecol 2002; 45: 205-17
87. Dmochowski RR. (S)-oxybutynin (Sepracor). Curr Opin Investig Drugs 2002; 3: 1508-11
88. (S)-oxybutynin (data on file). Marlborough (MA): Sepracor, 2004
89. Stengel PW, Gomeza J, Wess J, et al. M(2) and M(4) receptor knockout mice: muscarinic receptor function in cardiac and smooth muscle in vitro. J Pharmacol Exp Ther 2000; 292: 877-85